Lupin Launches Glucagon Drug

  Published 8 months ago

Lupin launches bioequivalent Glucagon for Injection for severe hypoglycaemia and diagnostics, targeting $122 million U.S. market.

  • Treats severe hypoglycaemia in diabetic adults and children, and reduces gastrointestinal motility during radiologic examinations.
  • Glucagon emergency kit, 1 mg/vial, generated $122 million annual U.S. sales according to IQVIA MAT June 2025.
  • Lupin, headquartered in Mumbai, distributes branded, generic, biotech, and API products to over 100 markets globally.

You might like these

Tesla Spain Sales Rise 60.7% in June Amid EV Growth

Apple Unveils AI Open-Source Plan, OS Redesign

ITC Q1 Profit Beats; Cigarette Volumes Surge

Raymond Slips 2.5% Post Q1 Miss

TCS to Hike Pay for 80% Staff from Sept

Hathway Q1 PBT Surges 59%

IndiGo Shares Volatile After Q1 Miss

News that matters the most ⚡